Imagine trying to find the right key for a lock when you have no map and the lock keeps changing. This project creates a giant, shared digital ledger to track how different leukemia patients respond to various treatments. By comparing aggressive chemotherapy against gentler, biology-based options in real-world settings, they can figure out which path actually saves more lives.
There is no standard of care for relapsed or refractory AML, leading to inconsistent treatment quality and poor patient outcomes. Current clinical trials often exclude vulnerable groups, leaving a gap in real-world evidence for diverse patient populations.
The STREAM platform for standardized clinical data collection and a Randomized Pragmatic Clinical Trial (RPCT) protocol to compare treatment intensities.
If you are a drug developer dealing with high failure rates in late-stage leukemia trials — this project developed the STREAM platform that standardizes clinical data. This allows for more accurate patient selection and real-world evidence generation for new therapies.
If you are a telemedicine provider dealing with limited access to specialist care in remote areas — this project developed telemedicine pilots in Ukraine and Tanzania. This proves how to extend high-quality cancer care to lower-resource settings.
If you are a biotech firm dealing with the need for high-quality tissue samples for MRD analysis — this project developed standardized operating procedures for biobanking. This ensures consistent sample quality across 7 different countries.
Based on available project data, specific pricing or implementation costs for the platform are not provided.
The project is designed for scale, utilizing a network of 18 partners across 7 countries to create a representative dataset from 340 patients.
Based on available project data, the project promotes open science through data sharing, but specific licensing terms for the biobanking SOPs are not listed.
The project involves regulatory bodies within its network to set new standards in AML treatment across Europe and beyond.
The project period runs from 2023-04-01 to 2028-03-31, with the STREAM platform already launched in the first 18 months.
The consortium is heavily weighted toward research and clinical expertise, with 10 research organizations and 5 universities. While industry representation is low at 6% (1 company), the inclusion of 2 SMEs and partners across 7 countries suggests a strong focus on clinical validation and cross-border standardization rather than immediate commercial productization.
Contact ISTITUTO ROMAGNOLO PER LO STUDIO DEI TUMORI DINO AMADORI - IRST SRL in Italy
Contact us to explore data-sharing partnerships with the STREAM platform.
